645 SERUM CARBONIC ANHYDRASE 9 (CA) IS A VALUABLE BIOMARKER (BM) TO PROFILE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB AND PREDICT THEIR OUTCOME

María Reig; Loreto Boix; Alejandro Forner; Jordi Rimola; Carlos Rodríguez de Lope; J.M. López-Oliva; Silvia Tremosini; Neus Llarch; Josep M. Llovet; Carmen Ayuso; Jordi Bruix

doi:10.1016/s0168-8278(11)60647-8

Shared by

Josep M. Llovet

645 SERUM CARBONIC ANHYDRASE 9 (CA) IS A VALUABLE BIOMARKER (BM) TO PROFILE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB AND PREDICT THEIR OUTCOME

Journal of Hepatology 54: S260-S261

Article 2011 English

Authors

MR
María Reig
LB
Loreto Boix
AF
Alejandro Forner

Abstract

1 min read

No abstract is provided for this article.

Related publications

Article2016

Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)

Josep M. Llovet, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean–Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Heiko Krissel, Ho Yeong Lim

Spiral (Imperial College London)

Letter2017

Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma”

Jordi Bruix, Ann‐Lii Cheng, Josep M. Llovet

Journal of Hepatology

Article2010

227 CHANGES IN TUMOR BLOOD VOLUME AND PERFUSION ASSESSED PERFUSION COMPUTED TOMOGRAPHY PREDICT THE TIMING OF TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB

María Reig, Jordi Rimola, Alejandro Forner, Carlos Rodríguez de Lope, Silvia Tremosini, Carmen Ayuso, Josep M. Llovet, Jordi Bruix

Journal of Hepatology

Article2004

261 Exclusion of subcapsular tumors prevents peritoneal seeding in hepatocellular carcinoma (HCC) patients treated with radiofrequency

Fernando Pons, Mattia Squarcia, R. Vilana, Margaret Sala, Luca Bianchi, M García Ayuso, Marı́a Varela, Josep M. Llovet, C. Brú, Jordi Bruix

Journal of Hepatology

Article2009

814 EVALUATION OF TUMOR PERFUSION AT COMPUTED TOMOGRAPHY AS A TOOL TO DETECT THE EFFECT OF SORAFENIB TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

María Reig, Jordi Rimola, Alejandro Forner, Carlos Rodríguez de Lope, Josep M. Llovet, Carmen Ayuso, Jordi Bruix

Journal of Hepatology

645 SERUM CARBONIC ANHYDRASE 9 (CA) IS A VALUABLE BIOMARKER (BM) TO PROFILE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB AND PREDICT THEIR OUTCOME

Abstract

Discussion(0)

Related publications

Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)

Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma”

227 CHANGES IN TUMOR BLOOD VOLUME AND PERFUSION ASSESSED PERFUSION COMPUTED TOMOGRAPHY PREDICT THE TIMING OF TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB

261 Exclusion of subcapsular tumors prevents peritoneal seeding in hepatocellular carcinoma (HCC) patients treated with radiofrequency

814 EVALUATION OF TUMOR PERFUSION AT COMPUTED TOMOGRAPHY AS A TOOL TO DETECT THE EFFECT OF SORAFENIB TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)